Emcure Q2 FY26: Revenue up 13%, PAT up 25% YoY

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.9%Reaction day

₹1422.50

prior close

₹1402.10

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-3.8% vs market

Pharmaceuticals peers, median of 157sector-0.2%-3.7% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Smallcap 250 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

-0.2

15m

-1.1

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.9-0.1-3.8-0.2-3.7

Next day

-6.0+0.6-6.6+0.5-6.5

-3.0+0.2-3.2+0.6-3.6

-3.6+0.4-3.9+0.5-4.0

-2.3+1.0-3.3+0.4-2.7

-4.3+0.0-4.3-0.6-3.8

-4.3-0.5-3.8-1.1-3.2

15d

-2.6-1.9-0.7-2.0-0.6

-1.2-4.5+3.3-3.2+2.0

+5.1-5.4+10.5-5.9+11.0

+5.1-3.8+8.9-6.4+11.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure reported Q2 FY26 consolidated revenue of Rs 2,270 Cr, up 13.4% YoY. PAT grew 24.7% YoY to Rs 251 Cr; H1 FY26 PAT at Rs 466 Cr versus Rs 354 Cr, up about 32%. EBITDA rose 15.2% to Rs 439 Cr with margins at 19.3%, up from 19.0%. Domestic sales grew 10.6% to Rs 1,031 Cr, international up 15.8% to Rs 1,238 Cr led by 23% growth in Europe. H1 revenue at Rs 4,371 Cr. Zuventus became wholly owned subsidiary from October 2025. Exceptional item of Rs 35 million for legal settlement.

Likely market impact

Strong double-digit revenue growth, expanding EBITDA margins and high-20s H1 PAT growth signal healthy momentum; positive for shareholders.